Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals

Tsafrir Greenberg, Jay C. Fournier, Richelle Stiffler, Henry W. Chase, Jorge R. Almeida, Haris Aslam, Thilo Deckersbach, Crystal Cooper Cortes, Marisa Toups, Thomas J Carmody, Benji Kurian, Scott Peltier, Phillip Adams, Melvin G. McInnis, Maria A. Oquendo, Maurizio Fava, Ramin Parsey, Patrick J. McGrath, Myrna Weissman, Madhukar H Trivedi & 1 others Mary L. Phillips

Research output: Contribution to journalArticle

Abstract

Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.

Original languageEnglish (US)
JournalMolecular Psychiatry
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Corpus Striatum
Sertraline
Reward
Placebos
Major Depressive Disorder
Antidepressive Agents
Depression
Neurotransmitter Agents
Dopamine
Serotonin
Magnetic Resonance Imaging
Demography
Ventral Striatum
Learning

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Greenberg, T., Fournier, J. C., Stiffler, R., Chase, H. W., Almeida, J. R., Aslam, H., ... Phillips, M. L. (Accepted/In press). Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0490-5

Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. / Greenberg, Tsafrir; Fournier, Jay C.; Stiffler, Richelle; Chase, Henry W.; Almeida, Jorge R.; Aslam, Haris; Deckersbach, Thilo; Cooper Cortes, Crystal; Toups, Marisa; Carmody, Thomas J; Kurian, Benji; Peltier, Scott; Adams, Phillip; McInnis, Melvin G.; Oquendo, Maria A.; Fava, Maurizio; Parsey, Ramin; McGrath, Patrick J.; Weissman, Myrna; Trivedi, Madhukar H; Phillips, Mary L.

In: Molecular Psychiatry, 01.01.2019.

Research output: Contribution to journalArticle

Greenberg, T, Fournier, JC, Stiffler, R, Chase, HW, Almeida, JR, Aslam, H, Deckersbach, T, Cooper Cortes, C, Toups, M, Carmody, TJ, Kurian, B, Peltier, S, Adams, P, McInnis, MG, Oquendo, MA, Fava, M, Parsey, R, McGrath, PJ, Weissman, M, Trivedi, MH & Phillips, ML 2019, 'Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals', Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0490-5
Greenberg, Tsafrir ; Fournier, Jay C. ; Stiffler, Richelle ; Chase, Henry W. ; Almeida, Jorge R. ; Aslam, Haris ; Deckersbach, Thilo ; Cooper Cortes, Crystal ; Toups, Marisa ; Carmody, Thomas J ; Kurian, Benji ; Peltier, Scott ; Adams, Phillip ; McInnis, Melvin G. ; Oquendo, Maria A. ; Fava, Maurizio ; Parsey, Ramin ; McGrath, Patrick J. ; Weissman, Myrna ; Trivedi, Madhukar H ; Phillips, Mary L. / Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. In: Molecular Psychiatry. 2019.
@article{2879ecd5f35244a484086c19c2705dc5,
title = "Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals",
abstract = "Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.",
author = "Tsafrir Greenberg and Fournier, {Jay C.} and Richelle Stiffler and Chase, {Henry W.} and Almeida, {Jorge R.} and Haris Aslam and Thilo Deckersbach and {Cooper Cortes}, Crystal and Marisa Toups and Carmody, {Thomas J} and Benji Kurian and Scott Peltier and Phillip Adams and McInnis, {Melvin G.} and Oquendo, {Maria A.} and Maurizio Fava and Ramin Parsey and McGrath, {Patrick J.} and Myrna Weissman and Trivedi, {Madhukar H} and Phillips, {Mary L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41380-019-0490-5",
language = "English (US)",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals

AU - Greenberg, Tsafrir

AU - Fournier, Jay C.

AU - Stiffler, Richelle

AU - Chase, Henry W.

AU - Almeida, Jorge R.

AU - Aslam, Haris

AU - Deckersbach, Thilo

AU - Cooper Cortes, Crystal

AU - Toups, Marisa

AU - Carmody, Thomas J

AU - Kurian, Benji

AU - Peltier, Scott

AU - Adams, Phillip

AU - McInnis, Melvin G.

AU - Oquendo, Maria A.

AU - Fava, Maurizio

AU - Parsey, Ramin

AU - McGrath, Patrick J.

AU - Weissman, Myrna

AU - Trivedi, Madhukar H

AU - Phillips, Mary L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.

AB - Medications to treat major depressive disorder (MDD) are not equally effective across patients. Given that neural response to rewards is altered in MDD and given that reward-related circuitry is modulated by dopamine and serotonin, we examined, for the first time, whether reward-related neural activity moderated response to sertraline, an antidepressant medication that targets these neurotransmitters. A total of 222 unmedicated adults with MDD randomized to receive sertraline (n = 110) or placebo (n = 112) in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study completed demographic and clinical assessments, and pretreatment functional magnetic resonance imaging while performing a reward task. We tested whether an index of reward system function in the ventral striatum (VS), a key reward circuitry region, moderated differential response to sertraline versus placebo, assessed with the Hamilton Rating Scale for Depression (HSRD) over 8 weeks. We observed a significant moderation effect of the reward index, reflecting the temporal dynamics of VS activity, on week-8 depression levels (Fs ≥ 9.67, ps ≤ 0.002). Specifically, VS responses that were abnormal with respect to predictions from reinforcement learning theory were associated with lower week-8 depression symptoms in the sertraline versus placebo arms. Thus, a more abnormal pattern of pretreatment VS dynamic response to reward expectancy (expected outcome value) and prediction error (difference between expected and actual outcome), likely reflecting serotonergic and dopaminergic deficits, was associated with better response to sertraline than placebo. Pretreatment measures of reward-related VS activity may serve as objective neural markers to advance efforts to personalize interventions by guiding individual-level choice of antidepressant treatment.

UR - http://www.scopus.com/inward/record.url?scp=85071945722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071945722&partnerID=8YFLogxK

U2 - 10.1038/s41380-019-0490-5

DO - 10.1038/s41380-019-0490-5

M3 - Article

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

ER -